Alnylam presents positive 18-month results from helios-a phase 3 study of investigational vutrisiran in patients with hattr amyloidosis with polyneuropathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the helios-a phase 3 study of vutrisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis, met all secondary endpoints measured at 18 months in patients with hattr amyloidosis with polyneuropathy, including statistically significant improvements in neuropathy impairment, quality of life (qol
ALNY Ratings Summary
ALNY Quant Ranking